Example of Therapeutic Advances in Drug Safety format
Recent searches

Example of Therapeutic Advances in Drug Safety format Example of Therapeutic Advances in Drug Safety format Example of Therapeutic Advances in Drug Safety format Example of Therapeutic Advances in Drug Safety format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
Look Inside
Example of Therapeutic Advances in Drug Safety format Example of Therapeutic Advances in Drug Safety format Example of Therapeutic Advances in Drug Safety format Example of Therapeutic Advances in Drug Safety format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
open access Open Access

Therapeutic Advances in Drug Safety — Template for authors

Publisher: SAGE
Categories Rank Trend in last 3 yrs
Pharmacology (medical) #41 of 246 down down by 34 ranks
journal-quality-icon Journal quality:
High
calendar-icon Last 4 years overview: 122 Published Papers | 771 Citations
indexed-in-icon Indexed in: Scopus
last-updated-icon Last updated: 07/07/2020
Related journals
Insights
General info
Top papers
Popular templates
Get started guide
Why choose from SciSpace
FAQ

Related Journals

open access Open Access

Taylor and Francis

Quality:  
High
CiteRatio: 6.4
SJR: 1.187
SNIP: 1.192
open access Open Access

SAGE

Quality:  
High
CiteRatio: 6.1
SJR: 1.333
SNIP: 1.061
open access Open Access

SAGE

Quality:  
High
CiteRatio: 4.8
SJR: 1.164
SNIP: 1.22
open access Open Access
recommended Recommended

Hindawi

Quality:  
High
CiteRatio: 6.4
SJR: 0.822
SNIP: 2.064

Journal Performance & Insights

CiteRatio

SCImago Journal Rank (SJR)

Source Normalized Impact per Paper (SNIP)

A measure of average citations received per peer-reviewed paper published in the journal.

Measures weighted citations received by the journal. Citation weighting depends on the categories and prestige of the citing journal.

Measures actual citations received relative to citations expected for the journal's category.

6.3

15% from 2019

CiteRatio for Therapeutic Advances in Drug Safety from 2016 - 2020
Year Value
2020 6.3
2019 5.5
2018 4.2
2017 9.8
2016 7.3
graph view Graph view
table view Table view

1.196

12% from 2019

SJR for Therapeutic Advances in Drug Safety from 2016 - 2020
Year Value
2020 1.196
2019 1.072
2018 1.131
2017 1.494
2016 1.702
graph view Graph view
table view Table view

1.603

17% from 2019

SNIP for Therapeutic Advances in Drug Safety from 2016 - 2020
Year Value
2020 1.603
2019 1.371
2018 1.525
2017 2.499
2016 1.824
graph view Graph view
table view Table view

insights Insights

  • CiteRatio of this journal has increased by 15% in last years.
  • This journal’s CiteRatio is in the top 10 percentile category.

insights Insights

  • SJR of this journal has increased by 12% in last years.
  • This journal’s SJR is in the top 10 percentile category.

insights Insights

  • SNIP of this journal has increased by 17% in last years.
  • This journal’s SNIP is in the top 10 percentile category.

Therapeutic Advances in Drug Safety

Guideline source: View

All company, product and service names used in this website are for identification purposes only. All product names, trademarks and registered trademarks are property of their respective owners.

Use of these names, trademarks and brands does not imply endorsement or affiliation. Disclaimer Notice

SAGE

Therapeutic Advances in Drug Safety

Approved by publishing and review experts on SciSpace, this template is built as per for Therapeutic Advances in Drug Safety formatting guidelines as mentioned in SAGE author instructions. The current version was created on 06 Jul 2020 and has been used by 595 authors to write and format their manuscripts to this journal.

Pharmacology (medical)

Medicine

i
Last updated on
06 Jul 2020
i
ISSN
2042-0986
i
Impact Factor
Medium - 0.721
i
Open Access
No
i
Sherpa RoMEO Archiving Policy
Green faq
i
Plagiarism Check
Available via Turnitin
i
Endnote Style
Download Available
i
Bibliography Name
SageV
i
Citation Type
Numbered (Superscripted)
25
i
Bibliography Example
Blonder GE, Tinkham M and Klapwijk TM. Transition from metallic to tunneling regimes in superconducting microconstrictions: Excess current, charge imbalance, and supercurrent conversion. Phys. Rev. B 1982; 25(7): 4515–4532. URL 10.1103/PhysRevB.25.4515.

Top papers written in this journal

open accessOpen access Journal Article DOI: 10.1177/2042098614554919
Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem:
Carl Llor1, Lars Bjerrum2

Abstract:

Antimicrobial resistance is a global public health challenge, which has accelerated by the overuse of antibiotics worldwide. Increased antimicrobial resistance is the cause of severe infections, complications, longer hospital stays and increased mortality. Overprescribing of antibiotics is associated with an increased risk of... Antimicrobial resistance is a global public health challenge, which has accelerated by the overuse of antibiotics worldwide. Increased antimicrobial resistance is the cause of severe infections, complications, longer hospital stays and increased mortality. Overprescribing of antibiotics is associated with an increased risk of adverse effects, more frequent re-attendance and increased medicalization of self-limiting conditions. Antibiotic overprescribing is a particular problem in primary care, where viruses cause most infections. About 90% of all antibiotic prescriptions are issued by general practitioners, and respiratory tract infections are the leading reason for prescribing. Multifaceted interventions to reduce overuse of antibiotics have been found to be effective and better than single initiatives. Interventions should encompass the enforcement of the policy of prohibiting the over-the-counter sale of antibiotics, the use of antimicrobial stewardship programmes, the active participation of clinicians in audits, the utilization of valid rapid point-of-care tests, the promotion of delayed antibiotic prescribing strategies, the enhancement of communication skills with patients with the aid of information brochures and the performance of more pragmatic studies in primary care with outcomes that are of clinicians’ interest, such as complications and clinical outcomes. read more read less

Topics:

Antimicrobial stewardship (63%)63% related to the paper, Antibiotic resistance (51%)51% related to the paper
View PDF
977 Citations
open accessOpen access Journal Article DOI: 10.1177/2042098614524430
Safety evaluation and risk assessment of electronic cigarettes as tobacco cigarette substitutes: a systematic review
Konstantinos Farsalinos, Riccardo Polosa1

Abstract:

Electronic cigarettes are a recent development in tobacco harm reduction. They are marketed as less harmful alternatives to smoking. Awareness and use of these devices has grown exponentially in recent years, with millions of people currently using them. This systematic review appraises existing laboratory and clinical resear... Electronic cigarettes are a recent development in tobacco harm reduction. They are marketed as less harmful alternatives to smoking. Awareness and use of these devices has grown exponentially in recent years, with millions of people currently using them. This systematic review appraises existing laboratory and clinical research on the potential risks from electronic cigarette use, compared with the well-established devastating effects of smoking tobacco cigarettes. Currently available evidence indicates that electronic cigarettes are by far a less harmful alternative to smoking and significant health benefits are expected in smokers who switch from tobacco to electronic cigarettes. Research will help make electronic cigarettes more effective as smoking substitutes and will better define and further reduce residual risks from use to as low as possible, by establishing appropriate quality control and standards. read more read less

Topics:

Tobacco harm reduction (65%)65% related to the paper, Smoking Tobacco (59%)59% related to the paper, Harm reduction (51%)51% related to the paper
View PDF
517 Citations
open accessOpen access Journal Article DOI: 10.1177/2042098611435911
Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource

Abstract:

Since its inception in the mid-1980s, the General Practice Research Database (GPRD) has undergone many changes but remains the largest validated and most utilised primary care database in the UK. Its use in pharmacoepidemiology stretches back many years with now over 800 original research papers. Administered by the Medicines... Since its inception in the mid-1980s, the General Practice Research Database (GPRD) has undergone many changes but remains the largest validated and most utilised primary care database in the UK. Its use in pharmacoepidemiology stretches back many years with now over 800 original research papers. Administered by the Medicines and Healthcare products Regulatory Agency since 2001, the last 5 years have seen a rebuild of the database processing system enhancing access to the data, and a concomitant push towards broadening the applications of the database. New methodologies including real-world harm-benefit assessment, pharmacogenetic studies and pragmatic randomised controlled trials within the database are being implemented. A substantive and unique linkage program (using a trusted third party) has enabled access to secondary care data and disease-specific registry data as well as socio-economic data and death registration data. The utility of anonymised free text accessed in a safe and appropriate manner is being explored using simple and more complex techniques such as natural language processing. read more read less

Topics:

Health care (50%)50% related to the paper
View PDF
295 Citations
open accessOpen access Journal Article DOI: 10.1177/2042098615615472
Predicting risk of adverse drug reactions in older adults
Amanda Hanora Lavan1, Paul Gallagher1

Abstract:

Adverse drug reactions (ADRs) are common in older adults, with falls, orthostatic hypotension, delirium, renal failure, gastrointestinal and intracranial bleeding being amongst the most common clinical manifestations. ADR risk increases with age-related changes in pharmacokinetics and pharmacodynamics, increasing burden of co... Adverse drug reactions (ADRs) are common in older adults, with falls, orthostatic hypotension, delirium, renal failure, gastrointestinal and intracranial bleeding being amongst the most common clinical manifestations. ADR risk increases with age-related changes in pharmacokinetics and pharmacodynamics, increasing burden of comorbidity, polypharmacy, inappropriate prescribing and suboptimal monitoring of drugs. ADRs are a preventable cause of harm to patients and an unnecessary waste of healthcare resources. Several ADR risk tools exist but none has sufficient predictive value for clinical practice. Good clinical practice for detecting and predicting ADRs in vulnerable patients includes detailed documentation and regular review of prescribed and over-the-counter medications through standardized medication reconciliation. New medications should be prescribed cautiously with clear therapeutic goals and recognition of the impact a drug can have on multiple organ systems. Prescribers should regularly review medication efficacy and be vigilant for ADRs and their contributory risk factors. Deprescribing should occur at an individual level when drugs are no longer efficacious or beneficial or when safer alternatives exist. Inappropriate prescribing and unnecessary polypharmacy should be minimized. Comprehensive geriatric assessment and the use of explicit prescribing criteria can be useful in this regard. read more read less

Topics:

Beers Criteria (62%)62% related to the paper, Adverse drug reaction (62%)62% related to the paper, Polypharmacy (60%)60% related to the paper, Deprescribing (59%)59% related to the paper, Risk assessment (51%)51% related to the paper
View PDF
262 Citations
open accessOpen access Journal Article DOI: 10.1177/2042098612454283
Drug-induced QT interval prolongation: mechanisms and clinical management
Senthil Nachimuthu1, Manish D. Assar1, Jeffrey M. Schussler1

Abstract:

The prolonged QT interval is both widely seen and associated with the potentially deadly rhythm, Torsades de Pointes (TdP). While it can occur spontaneously in the congenital form, there is a wide array of drugs that have been implicated in the prolongation of the QT interval. Some of these drugs have either been restricted o... The prolonged QT interval is both widely seen and associated with the potentially deadly rhythm, Torsades de Pointes (TdP). While it can occur spontaneously in the congenital form, there is a wide array of drugs that have been implicated in the prolongation of the QT interval. Some of these drugs have either been restricted or withdrawn from the market due to the increased incidence of fatal polymorphic ventricular tachycardia. The list of drugs that cause QT prolongation continues to grow, and an updated list of specific drugs that prolong the QT interval can be found at www.qtdrugs.org. This review focuses on the mechanism of drug-induced QT prolongation, risk factors for TdP, culprit drugs, prevention and monitoring of prolonged drug-induced QT prolongation and treatment strategies. read more read less

Topics:

QT interval (71%)71% related to the paper, Torsades de pointes (67%)67% related to the paper
View PDF
218 Citations
Author Pic

SciSpace is a very innovative solution to the formatting problem and existing providers, such as Mendeley or Word did not really evolve in recent years.

- Andreas Frutiger, Researcher, ETH Zurich, Institute for Biomedical Engineering

Get MS-Word and LaTeX output to any Journal within seconds
1
Choose a template
Select a template from a library of 40,000+ templates
2
Import a MS-Word file or start fresh
It takes only few seconds to import
3
View and edit your final output
SciSpace will automatically format your output to meet journal guidelines
4
Submit directly or Download
Submit to journal directly or Download in PDF, MS Word or LaTeX

(Before submission check for plagiarism via Turnitin)

clock Less than 3 minutes

What to expect from SciSpace?

Speed and accuracy over MS Word

''

With SciSpace, you do not need a word template for Therapeutic Advances in Drug Safety.

It automatically formats your research paper to SAGE formatting guidelines and citation style.

You can download a submission ready research paper in pdf, LaTeX and docx formats.

Time comparison

Time taken to format a paper and Compliance with guidelines

Plagiarism Reports via Turnitin

SciSpace has partnered with Turnitin, the leading provider of Plagiarism Check software.

Using this service, researchers can compare submissions against more than 170 million scholarly articles, a database of 70+ billion current and archived web pages. How Turnitin Integration works?

Turnitin Stats
Publisher Logos

Freedom from formatting guidelines

One editor, 100K journal formats – world's largest collection of journal templates

With such a huge verified library, what you need is already there.

publisher-logos

Easy support from all your favorite tools

Therapeutic Advances in Drug Safety format uses SageV citation style.

Automatically format and order your citations and bibliography in a click.

SciSpace allows imports from all reference managers like Mendeley, Zotero, Endnote, Google Scholar etc.

Frequently asked questions

1. Can I write Therapeutic Advances in Drug Safety in LaTeX?

Absolutely not! Our tool has been designed to help you focus on writing. You can write your entire paper as per the Therapeutic Advances in Drug Safety guidelines and auto format it.

2. Do you follow the Therapeutic Advances in Drug Safety guidelines?

Yes, the template is compliant with the Therapeutic Advances in Drug Safety guidelines. Our experts at SciSpace ensure that. If there are any changes to the journal's guidelines, we'll change our algorithm accordingly.

3. Can I cite my article in multiple styles in Therapeutic Advances in Drug Safety?

Of course! We support all the top citation styles, such as APA style, MLA style, Vancouver style, Harvard style, and Chicago style. For example, when you write your paper and hit autoformat, our system will automatically update your article as per the Therapeutic Advances in Drug Safety citation style.

4. Can I use the Therapeutic Advances in Drug Safety templates for free?

Sign up for our free trial, and you'll be able to use all our features for seven days. You'll see how helpful they are and how inexpensive they are compared to other options, Especially for Therapeutic Advances in Drug Safety.

5. Can I use a manuscript in Therapeutic Advances in Drug Safety that I have written in MS Word?

Yes. You can choose the right template, copy-paste the contents from the word document, and click on auto-format. Once you're done, you'll have a publish-ready paper Therapeutic Advances in Drug Safety that you can download at the end.

6. How long does it usually take you to format my papers in Therapeutic Advances in Drug Safety?

It only takes a matter of seconds to edit your manuscript. Besides that, our intuitive editor saves you from writing and formatting it in Therapeutic Advances in Drug Safety.

7. Where can I find the template for the Therapeutic Advances in Drug Safety?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Therapeutic Advances in Drug Safety's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

8. Can I reformat my paper to fit the Therapeutic Advances in Drug Safety's guidelines?

Of course! You can do this using our intuitive editor. It's very easy. If you need help, our support team is always ready to assist you.

9. Therapeutic Advances in Drug Safety an online tool or is there a desktop version?

SciSpace's Therapeutic Advances in Drug Safety is currently available as an online tool. We're developing a desktop version, too. You can request (or upvote) any features that you think would be helpful for you and other researchers in the "feature request" section of your account once you've signed up with us.

10. I cannot find my template in your gallery. Can you create it for me like Therapeutic Advances in Drug Safety?

Sure. You can request any template and we'll have it setup within a few days. You can find the request box in Journal Gallery on the right side bar under the heading, "Couldn't find the format you were looking for like Therapeutic Advances in Drug Safety?”

11. What is the output that I would get after using Therapeutic Advances in Drug Safety?

After writing your paper autoformatting in Therapeutic Advances in Drug Safety, you can download it in multiple formats, viz., PDF, Docx, and LaTeX.

12. Is Therapeutic Advances in Drug Safety's impact factor high enough that I should try publishing my article there?

To be honest, the answer is no. The impact factor is one of the many elements that determine the quality of a journal. Few of these factors include review board, rejection rates, frequency of inclusion in indexes, and Eigenfactor. You need to assess all these factors before you make your final call.

13. What is Sherpa RoMEO Archiving Policy for Therapeutic Advances in Drug Safety?

SHERPA/RoMEO Database

We extracted this data from Sherpa Romeo to help researchers understand the access level of this journal in accordance with the Sherpa Romeo Archiving Policy for Therapeutic Advances in Drug Safety. The table below indicates the level of access a journal has as per Sherpa Romeo's archiving policy.

RoMEO Colour Archiving policy
Green Can archive pre-print and post-print or publisher's version/PDF
Blue Can archive post-print (ie final draft post-refereeing) or publisher's version/PDF
Yellow Can archive pre-print (ie pre-refereeing)
White Archiving not formally supported
FYI:
  1. Pre-prints as being the version of the paper before peer review and
  2. Post-prints as being the version of the paper after peer-review, with revisions having been made.

14. What are the most common citation types In Therapeutic Advances in Drug Safety?

The 5 most common citation types in order of usage for Therapeutic Advances in Drug Safety are:.

S. No. Citation Style Type
1. Author Year
2. Numbered
3. Numbered (Superscripted)
4. Author Year (Cited Pages)
5. Footnote

15. How do I submit my article to the Therapeutic Advances in Drug Safety?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Therapeutic Advances in Drug Safety's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

16. Can I download Therapeutic Advances in Drug Safety in Endnote format?

Yes, SciSpace provides this functionality. After signing up, you would need to import your existing references from Word or Bib file to SciSpace. Then SciSpace would allow you to download your references in Therapeutic Advances in Drug Safety Endnote style according to Elsevier guidelines.

Fast and reliable,
built for complaince.

Instant formatting to 100% publisher guidelines on - SciSpace.

Available only on desktops 🖥

No word template required

Typset automatically formats your research paper to Therapeutic Advances in Drug Safety formatting guidelines and citation style.

Verifed journal formats

One editor, 100K journal formats.
With the largest collection of verified journal formats, what you need is already there.

Trusted by academicians

I spent hours with MS word for reformatting. It was frustrating - plain and simple. With SciSpace, I can draft my manuscripts and once it is finished I can just submit. In case, I have to submit to another journal it is really just a button click instead of an afternoon of reformatting.

Andreas Frutiger
Researcher & Ex MS Word user
Use this template